The federal government is taking a new approach to overseeing one of the country's fastest-growing healthcare programs.
The 340B program spent $43.9 billion in 2021, supporting nearly 50,000 hospitals with discounted outpatient drugs. Cancer drugs constitute 41% of 340B purchases, with outpatient departments and ...
HRSA has approved implementation plans for 10 manufacturers participating in its revised 340B Rebate Model Pilot ...
PharmaForce today announced its 340B Rebate and Maximum Fair Price (MFP) solution, giving covered entities a single connected workflow to identify eligible claims, submit them, and track outcomes ...
On March 3, 2026, the U.S. District Court for the District of Columbia (“Court”) issued a seismic ruling effectively vacating several components of Health Resources and Services Administration’s ...
Ten drugmakers will see 21 of their drugs move from upfront discounts to after-the-fact payments in the drug discount program at the start of next year, an expansion from the Trump ...
More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...
WASHINGTON, DC, UNITED STATES, August 19, 2026 /EINPresswire.com/ — The Community Oncology Alliance (COA) has submitted comments to Senate Committee on Health ...
FORT MYERS, Fla., Sept. 17, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physician leaders Lucio N. Gordan, MD, president & managing physician, and David Wenk, MD, ...
One view of 340B and MFP rebate-eligible claims, from identification through payment — ready for the 1/1/2027 rebate model, regardless of your current 340B TPA CONSHOHOCKEN, Pa.--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results